- Home
- KXIN vs PRPO Comparison
KXIN vs PRPO Comparison
Compare KXIN & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KXIN | PRPO |
|---|---|---|
| Founded | 2015 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9M | 42.0M |
| IPO Year | 2017 | 2000 |
Fundamental Metrics
Financial Performance| Metric | KXIN | PRPO |
|---|---|---|
| Price | $1.09 | $27.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 888.4K | 138.5K |
| Earning Date | 11-26-2019 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.15 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,049,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $0.11 | $16.01 |
| 52 Week High | $22.00 | $33.63 |
Technical Indicators
Market Signals| Indicator | KXIN | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 14.55 | 49.58 |
| Support Level | $0.36 | $25.20 |
| Resistance Level | $1.28 | $29.20 |
| Average True Range (ATR) | 0.62 | 2.11 |
| MACD | -0.24 | -0.41 |
| Stochastic Oscillator | 10.30 | 24.60 |
Price Performance
Historical ComparisonAbout KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto dealership company mainly engaged in the sale of domestic and imported automobiles in China. The company provides new and used car buyers in China with access to a wide selection of used vehicles across its network of dealerships, with a focus on premium brands such as Audi, BMW, Mercedes-Benz, Land Rover, and Porsche. The company generates revenue from automobile sales and related services.
About PRPO Precipio Inc.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.